First Quarter 2026 Results / Quarterly Reports

Bayer Q1 2026 Media Update

Group sales rise 4.1 percent (Fx & portfolio adj.) to 13.405 billion euros, negative currency effect of 886 million euros
EBITDA before special items increases 9.0 percent to 4.453 billion euros, negative currency effect of 321 million euros
Crop Science posts higher sales (Fx & portfolio adj.) and substantial earnings growth
Pharmaceuticals sales at prior-year level (Fx & portfolio adj.), earnings down
Consumer Health registers higher sales (Fx & portfolio adj.) and slightly lower earnings
Core earnings per share rise 12.9 percent to 2.71 euros
Net income improves to 2.763 billion euros
Free cash flow declines to minus 2.320 billion euros due to settlement payments
Net financial debt at 32.518 billion euros
Focus on continued execution of strategic priorities